Literature DB >> 29738926

Viral envelope-specific antibodies in chronic hepatitis B virus infection.

Davide Corti1, Fabio Benigni2, Daniel Shouval3.   

Abstract

While the cellular immune response associated with acute and chronic HBV infection has been thoroughly studied, the B cell response in chronic hepatitis B and the role of antibodies raised against the HBV envelope antigens in controlling and prevention of infection requires further investigation. The detection of anti-HBs antibodies is considered as one of the biomarkers for functional cure of chronic hepatitis B virus infection, as well as for protective immunity. Indeed, vaccine-induced neutralizing anti-HBs antibodies have been shown to protect against HBV challenge. Yet, the therapeutic potential of viral envelope-specific antibodies and the mechanism involved in protection and prevention of cell-to-cell transmission warrants additional investigative efforts. In this review, we will provide a critical overview of the available preclinical and clinical literature supporting the putative role of active and passive vaccination and neutralizing envelope-specific antibodies for therapeutic intervention in combination regimens intended to cure persistent HBV infection.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29738926     DOI: 10.1016/j.coviro.2018.04.002

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  13 in total

1.  The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans.

Authors:  Danilo Di Bona; Janardan P Pandey; Anna Aiello; Massimo Bilancia; Giuseppina Candore; Calogero Caruso; Claudia Colomba; Giovanni Duro; Mattia Emanuela Ligotti; Luigi Macchia; Sergio Rizzo; Giulia Accardi
Journal:  Immunology       Date:  2019-11-12       Impact factor: 7.397

2.  Multiple epitopes of hepatitis B virus surface antigen targeted by human plasma-derived immunoglobulins coincide with clinically observed escape mutations.

Authors:  Sreya Tarafdar; Maria Luisa Virata; Hailing Yan; Lilin Zhong; Lu Deng; Yanqun Xu; Yong He; Evi Struble; Pei Zhang
Journal:  J Med Virol       Date:  2021-08-26       Impact factor: 20.693

Review 3.  Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection.

Authors:  Ilaria Montali; Andrea Vecchi; Marzia Rossi; Camilla Tiezzi; Amalia Penna; Valentina Reverberi; Diletta Laccabue; Gabriele Missale; Carolina Boni; Paola Fisicaro
Journal:  Biomedicines       Date:  2022-05-24

4.  Structural basis of sodium-dependent bile salt uptake into the liver.

Authors:  Kapil Goutam; Francesco S Ielasi; Els Pardon; Jan Steyaert; Nicolas Reyes
Journal:  Nature       Date:  2022-05-11       Impact factor: 69.504

Review 5.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

6.  Entering the spotlight: hepatitis B surface antigen-specific B cells.

Authors:  Christoph Neumann-Haefelin; Robert Thimme
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

Review 7.  An update on antiviral antibody-based biopharmaceuticals.

Authors:  Shahrzad Ahangarzadeh; Zahra Payandeh; Roghaye Arezumand; Kiana Shahzamani; Fatemeh Yarian; Abbas Alibakhshi
Journal:  Int Immunopharmacol       Date:  2020-07-06       Impact factor: 4.932

8.  Liver-Targeted Toll-Like Receptor 7 Agonist Combined With Entecavir Promotes a Functional Cure in the Woodchuck Model of Hepatitis B Virus.

Authors:  Kyle E Korolowizc; Bin Li; Xu Huang; Changsuek Yon; Evelyn Rodrigo; Manny Corpuz; David M Plouffe; Bhaskar V Kallakury; Manasa Suresh; Tom Y-H Wu; Andrew T Miller; Stephan Menne
Journal:  Hepatol Commun       Date:  2019-07-08

Review 9.  Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response.

Authors:  Zhiyong Ma; Ejuan Zhang; Shicheng Gao; Yong Xiong; Mengji Lu
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

10.  Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.

Authors:  Verena Hehle; Maxime Beretta; Maryline Bourgine; Malika Ait-Goughoulte; Cyril Planchais; Solen Morisse; Benjamin Vesin; Valérie Lorin; Thierry Hieu; Andrea Stauffer; Oriane Fiquet; Jordan D Dimitrov; Marie-Louise Michel; Marie-Noëlle Ungeheuer; Camille Sureau; Stanislas Pol; James P Di Santo; Hélène Strick-Marchand; Nadège Pelletier; Hugo Mouquet
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.